DHART SPORE Project 3 Phase 1 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML)

syn51133946

Created By NF Service nf-osi-service

dataType: chromatinActivity geneExpression genomicVariants image
studyName: DHART SPORE Project 3 Phase 1 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML)
dataStatus: Under Embargo
initiative: Developmental and HyperActive Ras Tumor Specialized Programs of Research Excellence
studyLeads: Kevin Shannon Mignon Loh
studyStatus: Completed
diseaseFocus: Neurofibromatosis type 1
institutions: University of California, San Francisco
fundingAgency: NIH-NCI
manifestation: JMML
relatedStudies: syn51133946 syn51298831 syn51133914 syn51133924
studyFileviewId: syn51133951
syn54700333
syn51133948
syn5714290
syn58615624
syn51133949
syn51133951
syn55770667
syn55845141
syn56526832

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

DHART SPORE Project 3 Phase 1 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML) page is loading…

DHART SPORE Project 3 Phase 1 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML)

syn51133946

Drop files to upload

DHART SPORE Project 3 Phase 1 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML) page is loading…